03 Microsoft

1. Company and research division. Microsoft Research AI for Science (BioEmu team led by Frank Noé); secondary item: Microsoft Security (Guardian Agents).

2. Date of publication / announcement. BioEmu-2 public preview announced 20 October 2026, according to a secondary aggregator citing the team announcement. The model card says 'Release date: October 2026'. Guardian Agents: Microsoft Security blog, 19 October 2026 (context).

3. Research title and field. BioEmu-2: a generative foundation model for biomolecular structure and dynamics. Field: AI for science, protein and biomolecular ensembles.

4. Research background. Static structure predictors (AlphaFold class) give one conformation. Function often depends on conformational ensembles, which are expensive to sample with molecular dynamics. BioEmu-1 (Science, 2025) emulated equilibrium ensembles of single protein chains, generating thousands of structures per hour on a single GPU.

5. Scientific innovation. All-atom generative ensembles extended to multi-chain complexes, ligands and nucleic acids, with structure prediction, equilibrium sampling and forward-in-time propagation.

6. Methodology. According to the model card: a diffusion-based all-atom score model of about 500M parameters. Inputs are sequence(s), an optional MSA, and contact and method conditioning. Output is an ensemble sampled by reverse diffusion. Training took place in August–September 2026; licence MIT. It requires Linux and an NVIDIA GPU, and context-parallel sampling needs 4 or more GPUs. Training data and benchmarks for v2 were not described in the sources reviewed.

7. Results. No v2 quantitative results were identified in primary sources at the time of writing. The baseline from BioEmu-1 (peer-reviewed, Science, July 2025) is relative free energies with about 1 kcal/mol accuracy versus millisecond-scale MD and experimental data. That figure applies to v1 only.

8. Scientific significance. If v2's accuracy holds for complexes and ligands, this moves ensemble emulation from single-chain proteins towards drug–target and protein–nucleic-acid systems, which matters for binding-site dynamics and cryptic pockets.

9. Technical limitations. Accuracy claims for v2 are not yet peer-reviewed. Generated ensembles are plausible samples, not physically guaranteed trajectories. Performance outside the training distribution (e.g. membrane proteins, large assemblies) is unknown. The hardware requirement ties it to NVIDIA GPUs.

10. Technology readiness and evidence type. Lab prototype / research public preview with open weights. Evidence type: preliminary (model card plus team announcement); v1 is peer-reviewed.

11. Competitive comparison. Comparable systems include AlphaFold-class static predictors and MD-based ensembles. No peer-reviewed v2-versus-competitor benchmark was found.

12. Future research (1–5 years) — FORECAST. FORECAST (1–5 years): peer-reviewed validation of v2 against MD and experimental ensembles (NMR, HDX); coupling with docking and free-energy pipelines in drug discovery; use for mechanism hypotheses in cardiovascular and oncology targets.

13. Original references.

• https://huggingface.co/microsoft/bioemu2
• https://www.microsoft.com/en-us/research/publication/scalable-emulation-of-protein-equilibrium-ensembles-with-generative-deep-learning/
• https://www.microsoft.com/en-us/security/blog/2026/10/19/agents-are-your-newest-insiders-security-must-move-at-their-speed/